Novanta, Inc. (NASDAQ:NOVT) Q2 2020 Earnings Conference Call August 6, 2020 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Joe Jagoda - CJS Securities Rick Eastman - Robert W. Baird Brian Drab - William Blair Operator Good morning. My name is Laura, and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Inc. 2020 Second Qu ...

Financial Data and Key Metrics Changes - In Q1 2020, the company reported revenue of $155.5 million, representing a 1% year-over-year decline on a reported basis and a 4% decline on an organic basis [25][48] - Adjusted EBITDA was $28 million, down 2% compared to Q1 2019 [26][62] - The company achieved a book-to-bill ratio of 1.06, indicating strong bookings driven by customers securing inventories against COVID-19 disruptions [26] Business Line Data and Key Metrics Changes - Medical markets accounted for 58% of total revenue, growing 6% year-over-year, while industrial markets declined by 10% year-over-year [50][52] - The vision segment saw a 5% year-over-year revenue growth, with a book-to-bill ratio of 1.11 [35] - The precision motion segment experienced a 22% revenue decline, but bookings grew by 15% year-over-year [39] - The photonics segment revenue decreased by 7%, with bookings declining by 4% year-over-year [42][43] Market Data and Key Metrics Changes - Sales to China increased by 2% year-over-year, while sales to the U.S. and Europe decreased by 3% year-over-year [54] - The company noted a stable business in diagnostics and ICU markets, with a rapid uptake in PCR molecular testing [32][38] Company Strategy and Development Direction - The company aims to maintain business continuity and ensure employee safety during the pandemic, focusing on innovation and customer support [11][20] - The long-term growth drivers in robotics, automation, and healthcare productivity are expected to remain relevant post-pandemic [46] - The company is committed to pursuing M&A opportunities as a priority for capital allocation [46][105] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the uncertainty in the operating environment due to COVID-19 but expressed confidence in the company's resilience and innovation pipeline [10][46] - The company expects revenue declines in Q2 and Q3, with a potential recovery in the medical business as elective procedures resume [72][76] - Management emphasized the importance of maintaining liquidity and cash flow during the economic downturn [67][88] Other Important Information - The company implemented cost control measures, including a reduction in executive compensation and a temporary halt to share repurchase programs [78][83] - The company has a strong liquidity position with $449 million available, including cash and unused credit facilities [67][87] Q&A Session Summary Question: What is the expected impact on gross margins due to product mix? - Management indicated that gross margins are expected to be impacted by COVID-related costs, which could significantly increase in the upcoming quarters [98][99] Question: Has the R&D budget changed? - The company plans to maintain a similar R&D budget, with a focus on priority programs that may shift based on market conditions [101][102] Question: What is the outlook for acquisitions in the current market? - Management believes that the current climate will create M&A opportunities, although activity may be limited in the first half of the year due to pandemic uncertainties [103][105] Question: How does the company view the recovery trajectory among its platforms? - Management expects medical consumables to recover first, followed by capital equipment as hospitals resume procedures [112][113] Question: What are the anticipated COVID-related costs in the upcoming quarters? - Management expects COVID-related costs to increase significantly in Q2, primarily affecting the cost of goods sold [125][126]

Novanta Inc. (NASDAQ:NOVT) Q4 2019 Earnings Conference Call February 26, 2020 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities Richard Eastman - Robert W. Baird Brian Drab - William Blair Operator Good morning. My name is Eileen and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Incorporated's ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35083 NOVANTA INC. (Exact name of registrant as specified in its charter) New Brunswick, Canada 98-0110412 (State or other jurisdiction of incorpor ...

| --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | A Trusted Technology Partner to Medical and Advanced Technology Equipment | | | | | | Manufacturers Nasdaq: NOVT January 2020 | | | | | SAFE HARBOR STATEMENT The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, and future events or performance are forward-looking statements t ...

Novanta, Inc. (NASDAQ:NOVT) Q3 2019 Earnings Conference Call November 5, 2019 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - CEO Robert Buckley - CFO Conference Call Participants Lee Jagoda - CJS Securities Brian Drab - William Blair Operator Good morning. My name is Francesco and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Incorporated 2019 Third Quarter Earnings Call. All lines have been placed on mute to ...

| --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | A Trusted Technology Partner to Medical and Advanced Technology Equipment | | | | | | Manufacturers Nasdaq: NOVT November 2019 | | | | | SAFE HARBOR STATEMENT The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, and future events or performance are forward-looking statements ...

Novanta, Inc. (NASDAQ:NOVT) Q2 2019 Results Conference Call August 6, 2019 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities Richard Eastman - Baird Brian Drab - William Blair Operator Good morning. My name is Judith, and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Incorporated 2019 Second Q ...

| --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | A Trusted Technology Partner to Medical and Advanced Technology Equipment | | | | | | Manufacturers Nasdaq: NOVT June 2019 | | | | | SAFE HARBOR STATEMENT The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, and future events or performance are forward-looking statements that ...

Novanta, Inc. (NASDAQ:NOVT) Q1 2019 Earnings Conference Call May 7, 2019 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - CEO Robert Buckley - CFO Conference Call Participants Lee Jagoda - CJS Securities Richard Eastman - Robert W. Baird Operator Good morning. My name is Chad and I'll be your conference operator today. At this time, I would like to welcome everyone to the Novanta Incorporated 2019 First Quarter Earnings Call. All lines have been placed on mute to preve ...